EUVIMEDEUVIMED entdecken
Crossref

Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models

Emelie Öhnstedt iD, Cristian Doñas, Kristel Parv, Yanhong Pang, Hava Lofton Tomenius, Macarena Carrasco López, Venkata Ram Gannavarapu, Jacqueline Choi, Maria Ovezik, Peter Frank, Margareth Jorvid, Stefan Roos und 2 weitere

American Journal of Physiology-Gastrointestinal and Liver Physiology · 2024

DOI: 10.1152/ajpgi.00022.2024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Physiology-Gastrointestinal and Liver Physiology, 2024. Verfasst von Emelie Öhnstedt und 13 weiteren Autor:innen. Beteiligte Einrichtung: Ilya Pharma AB, Uppsala, Sweden. Hauptthemen laut MEDLINE: Colitis, Limosilactobacillus reuteri, Chemokine CXCL12, Dextran Sulfate. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Ilya Pharma AB, BioX grant from STUND to Ilya Pharma, Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colitis symptoms are efficiently reduced by peroral administration of probiotic bacteria genetically modified to deliver CXCL12 locally to the inflamed intestine in several mouse models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColitisLimosilactobacillus reuteriChemokine CXCL12Dextran SulfateDisease Models, AnimalAnimalsMiceAdministration, OralRabbitsProbioticsMice, Inbred C57BLFemaleColonMale

Stichwörter der Autor:innen

ILP100Limosilactobacillus reutericolitisdrug deliveryimmunotherapies

Substanzen

Chemokine CXCL12Dextran SulfateCxcl12 protein, mouse

Autor:innen und Institutionen

  • Ilya Pharma AB, Uppsala, Sweden.
  • Division of Integrative Physiology, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
  • Department of Molecular Sciences, Swedish University of Agriculture, Uppsala, Sweden.
  • The Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

ORCID-Profile: Emelie Öhnstedt, Evelina Vågesjö, Mia Phillipson

Förderung

  • Ilya Pharma AB
  • BioX grant from STUND to Ilya Pharma
  • Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation)

Zitieren

APA

Öhnstedt, E., Doñas, C., Parv, K., Pang, Y., Lofton Tomenius, H., Carrasco López, M., Gannavarapu, V. R., Choi, J., Ovezik, M., Frank, P., Jorvid, M., Roos, S., Vågesjö, E., & Phillipson, M. (2024). Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://doi.org/10.1152/ajpgi.00022.2024

Vancouver

Öhnstedt E, Doñas C, Parv K, Pang Y, Lofton Tomenius H, Carrasco López M, et al. Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2024. doi:10.1152/ajpgi.00022.2024

BibTeX
@article{hnstedt2024,
  author = {Öhnstedt, Emelie and Doñas, Cristian and Parv, Kristel and Pang, Yanhong and Lofton Tomenius, Hava and Carrasco López, Macarena and Gannavarapu, Venkata Ram and Choi, Jacqueline and Ovezik, Maria and Frank, Peter and Jorvid, Margareth and Roos, Stefan and Vågesjö, Evelina and Phillipson, Mia},
  title = {Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models},
  journal = {American Journal of Physiology-Gastrointestinal and Liver Physiology},
  year = {2024},
  doi = {10.1152/ajpgi.00022.2024}
}
Kostenlos starten →